Effect of bacterial and host factors on Helicobacter pylori eradication therapy

Bibliography

• Eusebi LH, Zagari RM, Bazzoli F. Epidemiology of H. pylori infection. Helicobacter 2014;19(Suppl 1):1-5
   PubMed Web of Science ®Google Scholar
• Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: evidence for sustained race/ethnic disparities. Am J Epidemiol 2012;175(1):54-9
   PubMed Web of Science ®Google Scholar
• Hirayama Y, Kawai T, Otaki J, et al. Prevalence of Helicobacter pylori infection with healthy subjects in Japan. J Gastroenterol Hepatol 2014;29(Suppl 4):16-19
   PubMed Web of Science ®Google Scholar
• Asaka M, Kato M, Sakamoto N. Roadmap to eliminate gastric cancer with Helicobacter pylori eradication and consecutive surveillance in Japan. J Gastroenterol 2014;49(1):1-8
   PubMed Web of Science ®Google Scholar
• Chey WD, Wong BC; Practice Parameters Committee of the American College of G. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102(8):1808-25
   PubMed Web of Science ®Google Scholar
• Feng L, Wen MY, Zhu YJ, et al. Sequential Therapy or Standard Triple Therapy for Helicobacter pylori Infection: An Updated Systematic Review. Am J Therapeut 2015. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013;347:f4587
   PubMed Web of Science ®Google Scholar
• Yamaoka Y. Mechanisms of disease: Helicobacter pylori virulence factors. Nat Rev Gastroenterol Hepatol 2010;7(11):629-41
   PubMed Web of Science ®Google Scholar
• Broutet N, Tchamgoue S, Pereira E, et al. Risk factors for failure of Helicobacter pylori therapy--results of an individual data analysis of 2751 patients. Aliment Pharmacol Ther 2003;17(1):99-109
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors–emphasis on rabeprazole. Aliment Pharmacol Ther 1999;13(Suppl 3):27-36
   PubMed Web of Science ®Google Scholar
• Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol 2014;29(7):1371-86
   PubMed Web of Science ®Google Scholar
• Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for helicobacter pylori infection. J Gastroenterol Hepatol 2009;24(10):1587-600
   PubMed Web of Science ®Google Scholar
• Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12(4):275-8
   PubMed Web of Science ®Google Scholar
• Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007;56(4):475-9
   PubMed Web of Science ®Google Scholar
• Megraud F, Coenen S, Versporten A, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013;62(1):34-42
   PubMed Web of Science ®Google Scholar
• Sasaki M, Ogasawara N, Utsumi K, et al. Changes in 12-Year first-line eradication rate of Helicobacter pylori Based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin. J Clin Biochem Nutr 2010;47(1):53-8
   PubMed Web of Science ®Google Scholar
• Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15(5):460-6
   PubMed Web of Science ®Google Scholar
• Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut 2012;61(5):646-64
   PubMed Web of Science ®Google Scholar
• Ierardi E, Giorgio F, Losurdo G, et al. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013;19(45):8168-80
   PubMed Web of Science ®Google Scholar
• Binh TT, Shiota S, Suzuki R, et al. Discovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencing. J Antimicrob Chemother 2014;69(7):1796-803
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Uotani T, Sahara S, et al. Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. Helicobacter 2014;19(4):312-18
   PubMed Web of Science ®Google Scholar
• Camargo MC, Garcia A, Riquelme A, et al. The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109(4):485-95
   PubMed Web of Science ®Google Scholar
• Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007;146(8):556-63
   PubMed Web of Science ®Google Scholar
• Osato MS, Reddy R, Reddy SG, et al. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001;161(9):1217-20
   PubMed Web of Science ®Google Scholar
• Kim N, Kim JM, Kim CH, et al. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40(8):683-7
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006;23(1):35-44
   PubMed Web of Science ®Google Scholar
• Li Y, Huang X, Yao L, et al. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122(13-14):413-22
   PubMed Web of Science ®Google Scholar
• Molina-Infante J, Gisbert JP. Levofloxacin in first-line eradication regimens for Helicobacter pylori: better test antibiotic susceptibility before treating. Gut 2011;60(11):1605; author reply 1605-6
   PubMed Web of Science ®Google Scholar
• Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993;90(12):5791-5
   PubMed Web of Science ®Google Scholar
• Hatakeyama M. Anthropological and clinical implications for the structural diversity of the Helicobacter pylori CagA oncoprotein. Cancer Sci 2011;102(1):36-43
   PubMed Web of Science ®Google Scholar
• Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 2004;4(9):688-94
   Google Scholar
• Ohnishi N, Yuasa H, Tanaka S, et al. Transgenic expression of Helicobacter pylori CagA induces gastrointestinal and hematopoietic neoplasms in mouse. Proc Nat Acad Sci USA 2008;105(3):1003-8
   PubMed Web of Science ®Google Scholar
• Franco AT, Johnston E, Krishna U, et al. Regulation of gastric carcinogenesis by Helicobacter pylori virulence factors. Cancer Res 2008;68(2):379-87
   PubMed Web of Science ®Google Scholar
• Crabtree JE, Taylor JD, Wyatt JI, et al. Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology. Lancet 1991;338(8763):332-5
   PubMed Web of Science ®Google Scholar
• Huang JQ, Zheng GF, Sumanac K, et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003;125(6):1636-44
   PubMed Web of Science ®Google Scholar
• Maeda S, Yoshida H, Ikenoue T, et al. Structure of cag pathogenicity Island in Japanese Helicobacter pylori isolates. Gut 1999;44(3):336-41
   PubMed Web of Science ®Google Scholar
• Cover TL, Blanke SR. Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 2005;3(4):320-32
   PubMed Web of Science ®Google Scholar
• Rhead JL, Letley DP, Mohammadi M, et al. A new Helicobacter pylori vacuolating cytotoxin determinant, the intermediate region, is associated with gastric cancer. Gastroenterology 2007;133(3):926-36
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Yamaoka Y. The association of vacA genotype and Helicobacter pylori-related disease in Latin American and African populations. Clin Microbiol Infect 2009;15(9):835-42
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Kikuchi S, el-Zimaity HM, et al. Importance of Helicobacter pylori oipA in clinical presentation, gastric inflammation, and mucosal interleukin 8 production. Gastroenterology 2002;123(2):414-24
   PubMed Web of Science ®Google Scholar
• Ruggiero P, Peppoloni S, Rappuoli R, Del Giudice G. The quest for a vaccine against Helicobacter pylori: how to move from mouse to man? Microbes Inf 2003;5(8):749-56
   PubMed Web of Science ®Google Scholar
• Yamaoka Y, Kudo T, Lu H, et al. Role of interferon-stimulated responsive element-like element in interleukin-8 promoter in Helicobacter pylori infection. Gastroenterology 2004;126(4):1030-43
   PubMed Web of Science ®Google Scholar
• Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002;162(2):153-60
   PubMed Web of Science ®Google Scholar
• Lu H, Hsu PI, Graham DY, Yamaoka Y. Duodenal ulcer promoting gene of Helicobacter pylori. Gastroenterology 2005;128(4):833-48
   PubMed Web of Science ®Google Scholar
• Hussein NR, Argent RH, Marx CK, et al. Helicobacter pylori dupA is polymorphic, and its active form induces proinflammatory cytokine secretion by mononuclear cells. J Infect Dis 2010;202(2):261-9
   PubMed Web of Science ®Google Scholar
• Hussein NR. The association of dupA and Helicobacter pylori-related gastroduodenal diseases. Eur J Clin Microbiol Inf Dis 2010;29(7):817-21
   PubMed Web of Science ®Google Scholar
• Shiota S, Matsunari O, Watada M, et al. Systematic review and meta-analysis: the relationship between the Helicobacter pylori dupA gene and clinical outcomes. Gut Pathogens 2010;2(1):13
   PubMed Web of Science ®Google Scholar
• Imagawa S, Ito M, Yoshihara M, et al. Helicobacter pylori dupA and gastric acid secretion are negatively associated with gastric cancer development. J Med Microbiol 2010;59(Pt 12):1484-9
   PubMed Web of Science ®Google Scholar
• Shiota S, Nguyen LT, Murakami K, et al. Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol 2012;46(4):297-301
   PubMed Web of Science ®Google Scholar
• Ilver D, Arnqvist A, Ogren J, et al. Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging. Science 1998;279(5349):373-7
   PubMed Web of Science ®Google Scholar
• Yamaoka Y. Roles of Helicobacter pylori BabA in gastroduodenal pathogenesis. World J Gastroenterol 2008;14(27):4265-72
   PubMed Web of Science ®Google Scholar
• Toller IM, Neelsen KJ, Steger M, et al. Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. Proc Nat Acad Sci USA 2011;108(36):14944-9
   PubMed Web of Science ®Google Scholar
• Sheu BS, Sheu SM, Yang HB, et al. Host gastric Lewis expression determines the bacterial density of Helicobacter pylori in babA2 genopositive infection. Gut 2003;52(7):927-32
   PubMed Web of Science ®Google Scholar
• Lai YC, Wang TH, Huang SH, et al. Density of Helicobacter pylori may affect the efficacy of eradication therapy and ulcer healing in patients with active duodenal ulcers. World J Gastroenterol 2003;9(7):1537-40
   PubMed Web of Science ®Google Scholar
• Grayson ML, Eliopoulos GM, Ferraro MJ, Moellering RCJr. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbiol Inf Dis 1989;8(10):888-9
   PubMed Web of Science ®Google Scholar
• Goddard AF, Jessa MJ, Barrett DA, et al. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111(2):358-67
   PubMed Web of Science ®Google Scholar
• Scott D, Weeks D, Melchers K, Sachs G. The life and death of Helicobacter pylori. Gut 1998;43(Suppl 1):S56-60
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Evidence that the degree and duration of acid suppression are related to Helicobacter pylori eradication by triple therapy. Helicobacter 2007;12(4):317-23
   PubMed Web of Science ®Google Scholar
• Villoria A, Garcia P, Calvet X, et al. Meta-analysis: high-dose proton pump inhibitors vs standard dose in triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 2008;28(7):868-77
   PubMed Web of Science ®Google Scholar
• Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59(8):1143-53
   PubMed Web of Science ®Google Scholar
• Nishino M, Sugimoto M, Kodaira C, et al. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers. J Clin Pharmacol 2011;51(7):1079-86
   PubMed Web of Science ®Google Scholar
• Uotani T, Sugimoto M, Nishino M, et al. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol 2012;10(8):879-85
   PubMed Web of Science ®Google Scholar
• de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995;345(8953):817-20
   PubMed Web of Science ®Google Scholar
• de Morais SM, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269(22):15419-22
   PubMed Web of Science ®Google Scholar
• Marinac JS, Balian JD, Foxworth JW, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. Clin Pharmacol Ther 1996;60(2):138-44
   PubMed Web of Science ®Google Scholar
• Ishizaki T, Sohn DR, Kobayashi K, et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. Ther Drug Monit 1994;16(2):214-15
   PubMed Web of Science ®Google Scholar
• Inoue K, Yamazaki H, Shimada T. Linkage between the distribution of mutations in the CYP2C18 and CYP2C19 genes in the Japanese and Caucasian. Xenobiotica 1998;28(4):403-11
   PubMed Web of Science ®Google Scholar
• Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999;65(5):552-61
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther 2001;69(3):158-68
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Xiao F, et al. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther 2001;70(5):484-92
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Different dosage regimens of rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotype status. Clin Pharmacol Ther 2004;76(4):290-301
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Treatment strategy to eradicate Helicobacter pylori infection: impact of pharmacogenomics-based acid inhibition regimen and alternative antibiotics. Expert Opin Pharmacother 2007;8(16):2701-17
   PubMed Web of Science ®Google Scholar
• Noach LA, Bosma NB, Jansen J, et al. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand J Gastroenterol 1994;29(5):425-9
   PubMed Web of Science ®Google Scholar
• Jung HC, Kim JM, Song IS, Kim CY. Helicobacter pylori induces an array of pro-inflammatory cytokines in human gastric epithelial cells: quantification of mRNA for interleukin-8, -1 alpha/beta, granulocyte-macrophage colony-stimulating factor, monocyte chemoattractant protein-1 and tumour necrosis factor-alpha. J Gastroenterol Hepatol 1997;12(7):473-80
   PubMed Web of Science ®Google Scholar
• Wallace JL, Cucala M, Mugridge K, Parente L. Secretagogue-specific effects of interleukin-1 on gastric acid secretion. Am J Physiol 1991;261(4 Pt 1):G559-64
   PubMed Web of Science ®Google Scholar
• El-Omar EM, Carrington M, Chow WH, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 2000;404(6776):398-402
   PubMed Web of Science ®Google Scholar
• Takashima M, Furuta T, Hanai H, et al. Effects of Helicobacter pylori infection on gastric acid secretion and serum gastrin levels in Mongolian gerbils. Gut 2001;48(6):765-73
   PubMed Web of Science ®Google Scholar
• Stokkers PC, van Aken BE, Basoski N, et al. Five genetic markers in the interleukin 1 family in relation to inflammatory bowel disease. Gut 1998;43(1):33-9
   PubMed Web of Science ®Google Scholar
• Tarlow JK, Blakemore AI, Lennard A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91(4):403-4
   PubMed Web of Science ®Google Scholar
• Furuta T, El-Omar EM, Xiao F, et al. Interleukin 1beta polymorphisms increase risk of hypochlorhydria and atrophic gastritis and reduce risk of duodenal ulcer recurrence in Japan. Gastroenterology 2002;123(1):92-105
   PubMed Web of Science ®Google Scholar
• Hwang IR, Kodama T, Kikuchi S, et al. Effect of interleukin 1 polymorphisms on gastric mucosal interleukin 1beta production in Helicobacter pylori infection. Gastroenterology 2002;123(6):1793-803
   PubMed Web of Science ®Google Scholar
• Sugimoto M, Furuta T, Shirai N, et al. Influences of proinflammatory and anti-inflammatory cytokine polymorphisms on eradication rates of clarithromycin-sensitive strains of Helicobacter pylori by triple therapy. Clin Pharmacol Ther 2006;80(1):41-50
   PubMed Web of Science ®Google Scholar
• Higgins CF. ABC transporters: from microorganisms to man. Annu Rev Cell Biol 1992;8:67-113
   PubMedGoogle Scholar
• Higgins CF, Gottesman MM. Is the multidrug transporter a flippase? Trends Biochem Sci 1992;17(1):18-21
   PubMed Web of Science ®Google Scholar
• Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF. Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol 2001;364(6):551-7
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 2001;69(3):169-74
   PubMed Web of Science ®Google Scholar
• Beales IL, Calam J. Interleukin 1 beta and tumour necrosis factor alpha inhibit acid secretion in cultured rabbit parietal cells by multiple pathways. Gut 1998;42(2):227-34
   PubMed Web of Science ®Google Scholar
• Shibata J, Goto H, Arisawa T, et al. Regulation of tumour necrosis factor (TNF) induced apoptosis by soluble TNF receptors in Helicobacter pylori infection. Gut 1999;45(1):24-31
   PubMed Web of Science ®Google Scholar
• Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Nat Acad Sci USA 1997;94(7):3195-9
   PubMed Web of Science ®Google Scholar
• Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003;125(2):364-71
   PubMed Web of Science ®Google Scholar
• Lanas A, Garcia-Gonzalez MA, Santolaria S, et al. TNF and LTA gene polymorphisms reveal different risk in gastric and duodenal ulcer patients. Genes Immun 2001;2(8):415-21
   PubMed Web of Science ®Google Scholar
• Yea SS, Yang YI, Jang WH, et al. Association between TNF-alpha promoter polymorphism and Helicobacter pylori cagA subtype infection. J Clin Pathol 2001;54(9):703-6
   PubMed Web of Science ®Google Scholar
• Zambon CF, Fasolo M, Basso D, et al. Clarithromycin resistance, tumor necrosis factor alpha gene polymorphism and mucosal inflammation affect H. pylori eradication success. J Gastroint Sur 2007;11(11):1506-14; discussion 1514
   PubMed Web of Science ®Google Scholar
• Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther 2007;81(4):521-8
   PubMed Web of Science ®Google Scholar